Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study

Figures & data

Table 1. Characteristics of 7894 patients diagnosed with renal cell carcinoma in Denmark, 2006–2017 according to their Charlson Comorbidity Index score.

	Charlson Comorbidity Index score n (%)
	0	1–2	≥3	Total
	N = 5015	N = 2072	N = 807	7894
Age, median (IQR)	64 (16)	68 (14)	69 (12)	66 (15)
Men, n (%)	3260 (65)	1366 (66)	553 (69)	5179
Stage, n (%)
Localized or regional	2769 (55)	1198 (58)	452 (56)	4419
Advanced	795 (16)	237 (11)	74 (9)	1106
Unknown	1451 (29)	637 (31)	281 (35)	2369
Period of diagnosis, n (%)
2006–2008	935 (67)	357 (25)	110 (8)	1402
2009–2011	1205 (66)	439 (24)	173 (10)	1817
2012–2014	1296 (60)	609 (28)	242 (11)	2147
2015–2017	1579 (62)	667 (26)	282 (12)	2528
Total	5015 (64)	2072 (26)	807 (10)	7894

Table 2. Overall 1- and 5-year survival rates and 95% confidence intervals (CIs) for 7894 patients diagnosed with renal cell carcinoma in Denmark in 2006–2017 by Charlson Comorbidity Index score and calendar period of diagnosis.

	Charlson Comorbidity Index score
	All			<70 years			≥70 years
	0	1–2	≥3	0	1–2	≥3	0	1–2	≥3
2006–2008
N	935	357	110	687	206	62	248	151	48
Mean % 1-year (range)	78 (75–80)	72 (67–76)	71 (61–78)	79 (75–82)	73 (67–79)	73 (60–82)	74 (68–79)	69 (61–76)	67 (51–78)
Mean % 5-year (range)	57 (54–61)	46 (41–52)	39 (30–48)	60 (56–63)	54 (47–60)	41 (29–53)	51 (44–57)	36 (28–43)	33 (21–47)
2009–2011
N	1205	439	173	862	261	105	343	178	68
Mean % 1-year (range)	84 (82–86)	82 (78–86)	80 (73–85)	85 (83–88)	86 (81–90)	83 (74–89)	80 (75–83)	76 (69–81)	74 (61–82)
Mean % 5-year (range)	64 (61–66)	62 (58–67)	48 (40–55)	67 (64–70)	68 (62–73)	57 (47–66)	55 (50–60)	54 (46–61)	32 (22–44)
2012–2014
N	1296	609	242	884	343	136	412	266	106
Mean % 1-year (range)	86 (84–88)	85 (82–88)	78 (72–83)	89 (87–91)	88 (84–91)	79 (71–85)	78 (74–82)	82 (76–86)	76 (67–83)
Mean % 5-year (range)	69 (66–71)	62 (58–65)	44 (37–51)	74 (71–76)	67 (61–72)	53 (44–62)	58 (53–63)	54 (48–60)	30 (21–39)
2015–2017
N	1579	667	282	1056	349	135	523	318	147
Mean % 1-year (range)	87 (85–88)	86 (84–89)	83 (78–87)	88 (86–90)	90 (86–93)	87 (80–92)	84 (80–87)	82 (77–86)	78 (71–84)

Table 3. Overall 1– and 5–year survival rates and 95% confidence intervals (CIs) for 7894 patients diagnosed with renal cell carcinoma in Denmark in 2006–2017 by Charlson Comorbidity Index score and stage of the disease.

	Charlson Comorbidity Index score
	All			<70 years			≥70 years
	0	1–2	≥3	0	1–2	≥3	0	1–2	≥3
Localized or regional stage
N	2769	1198	452	1968	680	247	801	518	205
Mean % 1-year (range)	96 (95–97)	94 (92–95)	89 (85–91)	97 (97–98)	96 (94–97)	91 (87–94)	93 (91–94)	91 (88–93)	85 (80–90)
Mean % 5-year (range)	82 (81–84)	71 (68–74)	57 (51–63)	85 (83–87)	80 (76–83)	65 (58–72)	76 (72–79)	60 (54–65)	44 (34–53)
Advanced stage
N	795	237	74	570	142	36	225	95	38
Mean % 1-year (range)	48 (45–52)	43 (37–49)	36 (26–47)	51 (46–55)	48 (39–56)	36 (21–51)	43 (36–49)	34 (24–43)	34 (20–49)
Mean % 5-year (range)	16 (13–19)	12 (8–17)	–	17 (14–21)	15 (9–22)	–	10 (6–15)	4 (1–12)	–
Unknown stage
N	1451	637	281	951	337	155	500	300	126
Mean % 1-year (range)	81 (79–83)	76 (73–79)	75 (70–80)	84 (81–86)	81 (76–85)	77 (70–83)	75 (71–79)	71 (66–76)	72 (64–79)
Mean % 5-year (range)	62 (59–64)	53 (49–57)	44 (37–50)	67 (64–70)	60 (54–65)	53 (45–61)	51 (46–56)	45 (39–51)	30 (21–39)

Table 4. Age- and gender-stratified overall, 1- and 5-year mortality hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) according to Charlson Comorbidity Index score among 7894 patients diagnosed with renal cell carcinoma in Denmark in 2006–2017.

Charlson comorbidity index score	1-year mortality %	HR1-year	95% CI	5-year mortality %	HR5-year	95% CI	HRoverall	95% CI
All
0	16	1.00	–	38	1.00	–	1.00	–
1–2	17	1.00	(0.88–1.14)	46	1.13	(1.05–1.22)	1.15	(1.06–1.24)
≥3	20	1.20	(1.01–1.42)	54	1.50	(1.35–1.66)	1.56	(1.40–1.73)
< 70 years
0	14	1.00	–	33	1.00	–	1.00	–
1–2	14	0.96	(0.80–1.15)	39	1.10	(0.98–1.22)	1.09	(0.97–1.22)
≥3	18	1.21	(0.95–1.54)	46	1.21	(1.21–1.64)	1.44	(1.24–1.68)
≥ 70 years
0	20	1.00	–	48	1.00	–	1.00	–
1–2	21	1.05	(0.87–1.25)	55	1.17	(1.05–1.31)	1.22	(1.09–1.37)
≥3	34	1.20	(0.94–1.52)	63	1.60	(1.38–1.85)	1.70	(1.46–1.98)

Figure 1. Age- and gender-stratified mortality hazard ratios (HRs) with corresponding 95% confidence intervals (Cis) according to conditions listed in the Charlson Comorbidity Index among 7894 patients diagnosed with renal cell carcinoma in Denmark in 2006–2017.

Data availability statement

The data in this study are accessed through the Danish Health Data Authority. They are not publicly available due to Danish legislation.